Site icon Epomedicine

Pregabalin : Pharmacology

Pharmacokinetics

Recommended dose adjustments based on varying degrees of renal impairment

CrCl (mL/min)GabapentinPregabalin
59-30700 mg BD150 mg BD
100 mg TDS
29-15700 mg OD75 mg BD
50 mg TDS
<15300 mg OD75 mg OD
Hemodialysis supplemental doses post dialysis100-300 mg75-150 mg

Rowland Tozer Method

Q = 1 – [Fe * (1-KF)]

Q = drug dose adjustment factor

Fe = drug fraction excreted unchanged in urine

KF = ratio of patient’s CrCl to normal 120 ml/min

If CrCl = 60 ml/min, Fe = 0.98, KF = 0.5, Q = 0.51

i.e., Administer 50% dose at the normal dosing interval, or administer the normal dose at twice the dosing interval.

Click to expand

Therapeutic Drug Monitoring

The role of TDM Therapeutic Drug Monitoring for Pregabalin has not yet been established and a reference range for the drug has yet to be identified.

There are 2 published methods for the determination of serum pregabalin.

  1. HPLC with fluorescence detection
  2. HPLC analysis by UV detection

Therapeutic and toxic ranges are not well defined.

Therapeutic concentrations are reported to be from 2 to 5 mcg/ml, while toxicity may occur at concentrations above 10 mcg/ml.

Click to expand
Click to expand

Effects of other drugs on Pregabalin concentrations

Pharmacokinetic interactions with concurrently administered drugs are not expected because Pregabalin is neither bound to serum proteins not metabolized.

A study suggested that enzyme inducers AEDs (e.g., carbamazepine) can moderately decrease pregabalin serum concentration by +/- 20-30%.

Exit mobile version